Inactive Instrument

Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Biotechnology & Medical Research

Acceleron Pharma Inc. Provides Revenue Guidance for the Quarter Ended June 30, 2020

August 06, 2020 at 07:33 am EDT

Acceleron Pharma Inc. provided revenue guidance for the quarter ended June 30, 2020. The Company expects to report royalty revenue of approximately $11.1 million from net sales of REBLOZYL in the United States for the quarter ended June 30, 2020.

Latest news about Acceleron Pharma Inc.

Global markets live: Airbus, BP, Merck, Pfizer, Meta...	21-12-08
Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl	21-12-03	DJ
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Biotechnology Index	21-11-22	CI
Merck Completes Acceleron Pharma Acquisition	21-11-22	MT
Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share	21-11-22	MT
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Composite Index	21-11-22	CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Global BMI Index	21-11-22	CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P TMI Index	21-11-22	CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Biotechnology Select Industry Index	21-11-22	CI
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc	21-11-19	CI
Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro Capital Advisors LLC, Holocene Advisors, LP, Darwin Global Management Limited and others for $7.1 billion.	21-11-18	CI
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offer	21-11-17	MT
Merck Extends Tender Offer for Acceleron Pharma	21-11-17	MT
Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Earnings Flash (XLRN) ACCELERON PHARMA Reports Q3 Loss $-0.95	21-11-04	MT
Merck Extends FTC Review Period for Acceleron Buyout	21-10-29	MT
Acceleron Pharma Sees Q3 Reblozyl Royalty Revenue at $32 Million Based on Net Sales of $160 Million	21-10-27	MT
Acceleron Pharma Inc. Provides Revenue Guidance for the Third Quarter Ended September 30, 2021	21-10-27	CI
Merck : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisition	21-10-21	MT
Merck : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Company	21-10-14	MT
Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron	21-10-13	RE
Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron	21-10-13	RE
Merck : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share	21-10-12	MT
ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target	21-10-07	MT

Chart Acceleron Pharma Inc.

Duration

Period

More charts

Company Profile

Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC). It generates multiple Fc-fusion protein ligand traps, IntelliTrap platform technology and a pipeline of clinical and preclinical therapeutic candidates targeting mechanisms underlying serious and rare diseases.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+2.90%	108B
REGENERON PHARMACEUTICALS, INC.	+10.02%	105B
ARGENX SE	+2.13%	23.46B
BIONTECH SE	-11.82%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-7.53%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.25%	13.99B
SAREPTA THERAPEUTICS, INC.	+35.51%	12.53B

Bio Therapeutic Drugs